Role of impulsivity and reward in the anti-obesity actions of 5-HT 2C receptor agonists

• Published in: Journal of psychopharmacology (Oxford) Vol. 31; no. 11; p. 1403
• Main Authors: Higgins, Guy A, Zeeb, Fiona D, Fletcher, Paul J
• Format: Journal Article
• Language: English
• Published: United States 01.11.2017
• Subjects: Animals; Anti-Obesity Agents - pharmacology; Anti-Obesity Agents - therapeutic use; Benzazepines - pharmacology; Benzazepines - therapeutic use; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Humans; Impulsive Behavior - drug effects; Obesity - drug therapy; Receptor, Serotonin, 5-HT2C - metabolism; Reward; Serotonin 5-HT2 Receptor Agonists - pharmacology; Serotonin 5-HT2 Receptor Agonists - therapeutic use; reward; Obesity; binge eating disorder; biomarkers; review; impulsivity; lorcaserin; 5-HT2C receptor
• ISSN: 1461-7285
• DOI: 10.1177/0269881117735797

The selective 5-HT receptor agonist lorcaserin entered clinical obesity trials with the prevalent view that satiety was a primary mechanism of action. Subsequent Phase II and III trials demonstrated efficacy in terms of weight loss, although the overall effect size (~3% placebo-corrected change) is...